Synthesis and biological activities of NB-506 analogues modified at the glucose group.
A new indolocarbazole compound, NB-506 (1), modified at the glucose group yielded a beta-D-glucopyranoside, J-107,088 (2), which showed potent anticancer activity. A beta-D-ribofuranoside, J-109,534 (3), was found to be 6 times more potent than J-107,088 at inhibiting topoisomerase I.
Ohkubo
M
M
Banyu Tsukuba Research Institute, Ibaraki, Japan.
Nishimura
T
T
Kawamoto
H
H
Nakano
M
M
Honma
T
T
Yoshinari
T
T
Arakawa
H
H
Suda
H
H
Morishima
H
H
Nishimura
S
S
D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000494:pharmacology*; D002227:Carbazoles / Q000138:chemical synthesis* / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology*; D005947:Glucose / Q000737:chemistry; D005960:Glucosides / Q000138:chemical synthesis* / Q000494:pharmacology*; D006801:Humans; D007211:Indoles; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D013237:Stereoisomerism; D059004:Topoisomerase I Inhibitors; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D002227:Carbazoles; D004791:Enzyme Inhibitors; D005960:Glucosides; D007211:Indoles; C092476:NB 506; D059004:Topoisomerase I Inhibitors; C121395:edotecarin; D005947:Glucose